The results turned out that knock-down of BTRC abolished the down-regulation of HuR, CDK6, and IGF1R expression upon enhanced expression of ASB16-AS1 in adrenocortical carcinoma cells (Fig. 7e). Here, BTRC is linked to adrenal cortex carcinoma.